Your trusted destination for CME, CPD & Medical Education across the Middle East.
Chase Lodge Hospital, United Kingdom
Professor Drew Provan, MBBS, MD, FRCP, FRCPath is a British hematologist and internationally recognized expert in immune thrombocytopenia (ITP), platelet disorders, autoimmune hematology, and classical hematology. He has spent much of his academic and clinical career at Queen Mary University of London (QMUL) and Barts Health NHS Trust, where he has been closely associated with the Academic Haematology Unit at the Blizard Institute. His research and clinical work have had a particularly strong influence on the diagnosis and management of primary immune thrombocytopenia, including international consensus recommendations.
| CategoryDetails | |
| Full name | Prof. Drew Provan |
| Profession | Consultant Hematologist, Academic Physician & Clinical Researcher |
| Specialty | Hematology / Classical Hematology |
| Main expertise | Immune thrombocytopenia, platelet disorders, autoimmune hematology, bleeding disorders |
| Academic institution | Queen Mary University of London |
| Research institute | Blizard Institute, Barts and The London School of Medicine and Dentistry |
| Clinical affiliation | Barts Health NHS Trust, London |
| Country | United Kingdom |
| Major research area | Immune thrombocytopenia (ITP) |
| Professional focus | Clinical research, guideline development, hematology education and patient management |
His publications identify his affiliation as the Academic Haematology Unit, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London.
Prof. Drew Provan is a British hematologist whose career has been particularly associated with the study of platelet disorders and immune thrombocytopenia (ITP). ITP is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production, potentially resulting in bleeding and thrombocytopenia.
His work has combined clinical hematology, academic research and international guideline development. Over the course of his career, he has become particularly recognized for research addressing how ITP should be diagnosed, classified and treated, and for helping establish internationally accepted approaches to its management.
Provan has been affiliated with the Academic Haematology Unit at the Blizard Institute, Queen Mary University of London, where his work has included clinical research and academic hematology. His research has involved collaboration with hematologists and investigators from Europe, North America, Asia and other regions.
One of Prof. Provan's most significant contributions has been his leadership in developing the International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia.
The original international consensus report was published in Blood in 2010, with Provan as the first author. The international expert panel addressed diagnosis and treatment of ITP in adults, children and pregnancy, while also considering the limitations of available clinical-trial evidence.
The report subsequently became an important international reference for physicians managing ITP.
In 2019, Provan again served as first author of the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia, published in Blood Advances. The updated report reviewed evidence published between 2009 and 2018 and incorporated developments in ITP treatment and understanding of the disease.
The 2019 consensus report covered:
Prof. Provan's scientific work has concentrated primarily on non-malignant hematology, particularly diseases involving platelets and immune-mediated blood disorders.
His later publications have continued to examine how ITP should be defined and managed in contemporary clinical practice. For example, he co-authored a 2023 review examining primary and secondary ITP and whether the conventional distinction between them should be reconsidered.
Prof. Provan's influence extends beyond individual research papers because he has participated in the development of international consensus recommendations.
The 2010 consensus report involved a large international expert panel including specialists from the United Kingdom, United States, Canada, France, Italy, Spain and other countries.
The updated 2019 report similarly brought together international ITP specialists and incorporated evidence from the preceding decade.
This work has positioned Provan as an important contributor to the international clinical framework for ITP diagnosis and treatment.
His career combines clinical hematology with academic research at Queen Mary University of London.
The Academic Haematology Unit at the Blizard Institute, Barts and The London School of Medicine and Dentistry, has been his principal academic affiliation in published research.
His clinical work has been associated with Barts Health NHS Trust, one of the major academic healthcare systems in London.
Through this combination of clinical practice and academic research, Provan has worked on translating hematology research into practical recommendations for physicians treating patients with platelet disorders.
Provan was first author of the landmark International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia, published in Blood in 2010.
The report addressed ITP diagnosis and treatment in adults, children and pregnancy and sought to provide consensus-based recommendations where high-quality trial evidence was limited.
He subsequently led the updated consensus report published in Blood Advances in 2019.
This update incorporated developments in ITP treatment and disease understanding from 2009–2018 and provided updated recommendations for diagnosis and management.
In 2023, Provan co-authored a comprehensive review examining primary and secondary ITP, emphasizing the similarities and differences between the two conditions and reviewing contemporary diagnostic and therapeutic approaches.
His publication record demonstrates continuing involvement in research addressing platelet counts, bleeding, treatment response and clinical outcomes in ITP. His work has also been cited extensively in subsequent research and clinical guidance concerning ITP.
| PeriodCareer / Achievement | |
| Early career | Developed specialization in hematology and platelet/immune disorders. |
| Academic career | Joined the academic hematology community associated with Barts and The London School of Medicine and Dentistry and Queen Mary University of London. |
| 2009 | Participated in the international working group that standardized terminology, definitions and outcome criteria for ITP. |
| 2010 | First author of the first International Consensus Report on investigation and management of primary ITP, published in Blood. |
| 2010s | Continued research and clinical work focused on ITP, platelet disorders and hematologic disease management. |
| 2019 | First author of the Updated International Consensus Report on primary ITP, published in Blood Advances. |
| 2020s | Continued international collaboration in clinical hematology, ITP research and guideline development. |
| 2023 | Co-authored a contemporary review addressing primary and secondary ITP and modern management approaches. |
| Current | Continues academic and clinical hematology work through Queen Mary University of London/Barts-associated hematology services. |
Prof. Provan's strongest areas of expertise can be summarized as:
Hematology
Immune thrombocytopenia
Academic medicine
Queen Mary University of London — Blizard Institute
Academic Haematology Unit
London, United Kingdom
His published research continues to identify him with the Academic Haematology Unit, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London.
For a MedArena speaker profile, his most significant credential is his role as a leading international contributor to ITP clinical guidance, particularly his first-author leadership of both the 2010 International Consensus Report and the 2019 Updated International Consensus Report on primary immune thrombocytopenia.
MeetingMinds Experts
MeetingMinds Experts